PPARG and type 2 diabetes mellitus: Downstream of PGD2 and its receptors, APPV717I (AD) mice treated with a PPARγ agonist (pioglitazone, a clinically approved drug for type 2 diabetes) exhibited a reduction in the number of activated microglia and reactive astrocytes in the hippocampus and cortex, consequently decreasing other inflammatory markers like COX-2 and inducible nitric oxide synthase [153].